Optimizing the dose and schedule of immune checkpoint inhibitors in cancer to allow global access. (2022)
Attributed to:
Developing Existing Healthcare Technologies to Deliver More Affordable and Effective Cancer Care
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/s41591-022-02029-1
PubMed Identifier: 36202999
Publication URI: http://europepmc.org/abstract/MED/36202999
Type: Journal Article/Review
Volume: 28
Parent Publication: Nature medicine
Issue: 11
ISSN: 1078-8956